Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PKCθ promotes c-Rel–driven mammary tumorigenesis in mice and humans by repressing estrogen receptor α synthesis
Karine Belguise, Gail E. Sonenshein
Karine Belguise, Gail E. Sonenshein
Published December 3, 2007
Citation Information: J Clin Invest. 2007;117(12):4009-4021. https://doi.org/10.1172/JCI32424.
View: Text | PDF
Research Article Oncology

PKCθ promotes c-Rel–driven mammary tumorigenesis in mice and humans by repressing estrogen receptor α synthesis

  • Text
  • PDF
Abstract

The vast majority of primary human breast cancer tissues display aberrant nuclear NF-κB c-Rel expression. A causal role for c-Rel in mammary tumorigenesis has been demonstrated using a c-Rel transgenic mouse model; however, tumors developed with a long latency, suggesting a second event is needed to trigger tumorigenesis. Here we show that c-Rel activity in the mammary gland is repressed by estrogen receptor α (ERα) signaling, and we identify an epigenetic mechanism in breast cancer mediated by activation of what we believe is a novel PKCθ-Akt pathway that leads to downregulation of ERα synthesis and derepression of c-Rel. ERα levels were lower in c-Rel–induced mammary tumors compared with normal mammary gland tissue. PKCθ induced c-Rel activity and target gene expression and promoted growth of c-Rel- and c-RelxCK2α–driven mouse mammary tumor–derived cell lines. RNA expression levels of PKCθ and c-Rel target genes were inversely correlated with ERα levels in human breast cancer specimens. PKCθ activated Akt, thereby inactivating forkhead box O protein 3a (FOXO3a) and leading to decreased synthesis of its target genes, ERα and p27Kip1. Thus we have shown that activation of PKCθ inhibits the FOXO3a/ERα/p27Kip1 axis that normally maintains an epithelial cell phenotype and induces c-Rel target genes, thereby promoting proliferation, survival, and more invasive breast cancer.

Authors

Karine Belguise, Gail E. Sonenshein

×

Figure 8

PKCθ activates Akt and promotes proliferation and migration of breast cancer cells.

Options: View larger image (or click on image) Download as PowerPoint
PKCθ activates Akt and promotes proliferation and migration of breast ca...
(A) WCEs from MCF7 and ZR75 cells transfected with 2 μg PKCθ-A/E or EV DNA (left panel) or rel-3875 cells transfected with 2 μg PKCθ-K/R or EV DNA were subjected to immunoblotting for phosphorylated Akt (p-Akt), total Akt, and β-actin. (B) ZR75 cells were transiently transfected in triplicate with 0.1 μg of proB-Luc vector (top panel) or p27-Luc vector (bottom panel) and β-gal, 0.2 μg PKCθ-A/E or EV DNA with either 0.1 or 0.2 μg Akt-DN or EV DNA. (C and D) The indicated cell lines stably expressing Akt-DN (C) or PKCθ-K/R (D) were subjected to either an MTS cell proliferation assay (C) or cell count (D). The values represent the mean ± SD. (E) MCF7 and ZR75 cells, transfected with 3 μg PKCθ-A/E or EV plus 6 μg SR-IκBα or EV, were subjected to a migration assay for 48 or 24 hours, respectively. Values represent mean ± SD of OD410nm. (F) In the normal mammary gland, active FOXO3a leads to synthesis of ERα and p27Kip1. ERα signaling inhibits c-Rel activity and expression of c-Rel target genes, and p27Kip1 induces cell cycle arrest. Activation of PKCθ during mammary tumorigenesis induces activated Akt, leading to 14-3-3–mediated nuclear export of FOXO3a. The resulting inhibition of ERα synthesis causes derepression of c-Rel activity. Cell proliferation and migration are promoted via induction of expression of c-Rel target genes as well as by the decrease in p27Kip1 synthesis.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts